AB Science Provides Update on Masitinib Development in Multiple Sclerosis
AB Science has provided an update on the development of masitinib for progressive forms of multiple sclerosis (MS) following the ECTRIMS 2024 congress. The company presented data from its Phase 3 studies.
Biopharmaceutical company AB Science has provided an update on the clinical development of masitinib for the treatment of progressive forms of multiple sclerosis (MS). The announcement follows the 2024 congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), where the company presented its latest findings.
AB Science is focused on investigating masitinib for rare and severe diseases. Many patients with progressive MS have limited treatment options, highlighting the need for new therapeutic approaches.
The company has made progress in its Phase 3 clinical studies designed to evaluate the efficacy and safety of masitinib in patients with specific types of progressive MS. The data presented at the ECTRIMS congress offer further insights into the drug's potential role in slowing disease progression.
AB Science's announcement emphasizes the ongoing Phase 3 studies and the analysis of new clinical data. The company continues to engage with regulatory authorities to advance masitinib for these indications.